Seaberg Karen’s SEC Form 4 filings reveal a pronounced sell-side bias concentrated entirely in MGP Ingredients (MGPI), with 45 total transactions over the reporting period. The aggregate figures are stark: open-market sales totaled roughly $17.5 million, dwarfing open-market purchases of about $427,000. The recent activity, spanning December 2025 back to March 2025, shows 22 open-market sales against just 2 purchases, a ratio that underscores a persistent disposition of shares rather than accumulation.
The most intense selling occurred in December 2025, with a cluster of transactions on December 8–10 totaling over $7.1 million. The largest single sale came on December 9, valued at approximately $4.04 million, followed by two sales on December 10 worth roughly $803,000 and $761,000. Earlier in the year, March 2025 also saw heavy selling, including a $2.24 million sale on March 11 and a $1.12 million transaction on March 12. The only open-market purchases in the recent window occurred on March 11, 2025, totaling about $427,000—a modest counterweight to the selling pressure that surrounded it.
Notably, the transaction codes clarify that most activity is discretionary: the “S” code denotes open-market sales, while the two “P” purchases represent the only conviction buys. Other filings, such as the zero-value “J” transaction in August 2025, reflect non-monetary adjustments. The pattern is unambiguous: Seaberg Karen has been a consistent net seller of MGPI shares, with selling accelerating in late 2025 and no recent purchases to suggest a shift in direction.
AI-assisted summary